Financial Analysis: Quotient Limited (QTNT) vs. TrovaGene (TROV)

Quotient Limited (NASDAQ: QTNT) and TrovaGene (NASDAQ:TROV) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, profitabiliy, institutional ownership, dividends and earnings.

Institutional and Insider Ownership

38.6% of Quotient Limited shares are owned by institutional investors. Comparatively, 18.2% of TrovaGene shares are owned by institutional investors. 40.5% of Quotient Limited shares are owned by company insiders. Comparatively, 7.4% of TrovaGene shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Quotient Limited and TrovaGene’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Quotient Limited $22.23 million 4.59 -$64.60 million ($3.01) -2.36
TrovaGene $355,623.00 114.09 -$35.52 million ($1.34) -0.98

TrovaGene has higher revenue, but lower earnings than Quotient Limited. Quotient Limited is trading at a lower price-to-earnings ratio than TrovaGene, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Quotient Limited and TrovaGene’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Quotient Limited -382.71% -1,303.22% -77.72%
TrovaGene -10,938.20% -162.31% -77.68%

Volatility and Risk

Quotient Limited has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500. Comparatively, TrovaGene has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for Quotient Limited and TrovaGene, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Quotient Limited 0 0 2 0 3.00
TrovaGene 1 0 2 0 2.33

Quotient Limited presently has a consensus target price of $19.00, suggesting a potential upside of 167.61%. TrovaGene has a consensus target price of $4.45, suggesting a potential upside of 239.69%. Given TrovaGene’s higher possible upside, analysts clearly believe TrovaGene is more favorable than Quotient Limited.

Quotient Limited Company Profile

Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market. It is engaged in developing MosaiQ, which is its technology platform. The Company develops, manufactures and commercializes the products, including antisera products, reagent red blood cells, whole blood controls and ancillary products. Its antisera products contain antibodies used to identify blood group antigens. Its antisera products are monoclonal antibodies manufactured from master cell lines it owns. Its reagent red blood cells products are composed of human red blood cells formulated to enable the identification of blood group antibodies. The Company develops, manufactures and sells conventional reagent products to original equipment manufacturers (OEMs).

TrovaGene Company Profile

Trovagene, Inc. (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. It has ongoing clinical collaborations to demonstrate the ability to determine and monitor mutational status and response to therapy in lung, colon, pancreatic and skin cancer. It uses its molecular diagnostic technology for the detection of cell-free deoxyribonucleic acid (DNA) originating from diseased cell death that can be isolated and detected from urine, blood and tissue samples to develop disease management.

Receive News & Ratings for Quotient Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient Limited and related companies with our FREE daily email newsletter.

 


Latest News

Todd Frazier Traded to Yankees for Blake Rutherford and Others
Todd Frazier Traded to Yankees for Blake Rutherford and Others
Tigers Would Include Cash in Verlander Deal and Other MLB Trade Rumors
Tigers Would Include Cash in Verlander Deal and Other MLB Trade Rumors
Todd Frazier Trade to Boston Appears to Be Decided
Todd Frazier Trade to Boston Appears to Be Decided
Chicago White Sox Continue Rebuild Without Jose Quintana
Chicago White Sox Continue Rebuild Without Jose Quintana
Mike Trout Returns from Injury With Single and Stole Base
Mike Trout Returns from Injury With Single and Stole Base
Chicago Cubs Strengthen Rotation Through Trade for Jose Quintana
Chicago Cubs Strengthen Rotation Through Trade for Jose Quintana


Leave a Reply

 
© 2006-2017 BBNS.